UnitedHealth Stock Buy or Sell? UNH Stocks Forecast

Market Capitalization: 482 394 604 000 $
EBITDA: 36 330 000 000 $
Price to Earnings: 21.89
Quarterly Earnings Growth YOY: 0.16
Quarterly Revenue Growth YOY: 0.141
Trailing PE: 21.89
Forward PE: 18.55
Shares Outstanding: 924925000

Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

UnitedHealth Stock Buy or Sell? UNH Stocks Analytic Forecasts

Updated on February 24, 2024 (09:14)

UnitedHealth Group, Inc. (UNH prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the UNH stock market. Experts share their opinions on what to expect from the UnitedHealth Group, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell UnitedHealth stocks.

UnitedHealth Group, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy UNH Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Kody’s Dividends and is titled

“UnitedHealth Group: Doubling Down On This Dividend Growth Machine”

is published on February 16 (2024) and has 0 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • When I make investments, I look for best-of-breed businesses operating in industries with lengthy growth runways.
  • UnitedHealth Group Incorporated revenue and adjusted diluted EPS climbed higher in Q4.
  • The health insurer enjoys an A+ credit rating from S&P on a stable outlook.
  • Shares of UnitedHealth Group could be undervalued by 7%.
  • The stock could be poised to meaningfully outperform the S&P over the next 10 years.

The author starts his analytic review with the following:

As a dividend growth investor, my job is to ensure that I build a portfolio that can deliver healthy dividend growth year in and year out. Why is this important?

The opinion of the author can be considered quite authoritative.
The number of 8293 followers confirms this.
Kody’s Dividends is the contributor of experts community
since 2018 and has 364 works published.

One more noteworthy article is written by JR Research under the title

“UnitedHealth: Rejoice When The Market Turns Fearful (Upgrade)”

on January 29 (2024) and has 3 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add UNH stocks to your investment portfolio or not, and helps to work out your own UnitedHealth stock selling strategies:

  • UnitedHealth Group stock was struck by fears over its health insurance business, attributed to the recent Humana steep earnings outlook downgrade.
  • However, UnitedHealth’s integrated healthcare model helps mitigate the impact of any one segment, improving its resilience.
  • Management believes recent uncertainties in the health insurance industry will not have a lasting effect on the company’s outlook.
  • I explain why UNH is no longer overvalued, with its recent price action suggesting capitulation has likely occurred.
  • I highlight why I’ve decided to turn bullish on UNH, urging investors to capitalize on its recent downside volatility to add more exposure.

JR Research starts analysis with such words:

UnitedHealth Group (NYSE:UNH) investors have underperformed the S&P 500 (SP500) over the past year, as UNH delivered a 1Y total return of 3.7%. However, it’s still much more impressive than Humana’s (HUM) -27% 1Y total return, as the company suffered a blowout following its recent earnings release, as management offered a significantly lowered 2024 guidance.

This author is very popular among the auditory. He has 31747 followers

JR Research is the contributor of experts community since 2021. Has published at least 1943 articles.

Another analysis presented by White Star Research came out on January 16 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for UNH stocks. It sounds like

“UnitedHealth: The Crown Jewel Of U.S. Health Insurance”

Article has got 0 likes at the moment and forecasting Bullish trend of the market.

Summarizing the information presented in the review concerning the UnitedHealth Group, Inc., the expert says the following:

  • UNH is the largest healthcare company globally, providing medical insurance through its UnitedHealthcare division and primary care, PBM and data analytics through its Optum business.
  • Since Q1 21, UNH’s insurance plans outperformed the industry by a wide margin with ~22% vs ~14% total $/member growth and an on average 360bps lower MLR.
  • Leveraging Optum, UNH’s margins are roughly double that of industry peers with significant future headroom due to high-growth data analytics and primary care adding 20-30bps of annual segment margin expansion.
  • Strong cash generation and potential relevering to 2.5x EBITDA could allow UNH to deploy up to $66bn towards share buybacks (~14% of current market cap) or value-accretive M&A in the coming years.
  • On the back of its best-in-class profile and undemanding current valuation at ~14% discount to 3Y average, I initiate UNH with a Buy rating and a PT of $635 (22% upside to current).

And here, what comes first:

Company Overview UnitedHealth Group (NYSE:UNH) is the largest health insurer in the US and the largest healthcare company globally with a current market cap of $482bn and FY23 revenues of $372bn. It currently operates through 2 segments which are roughly equal in size and together cover most of the commercial healthcare value chain from insurance plans over pharmacy benefit management (“PBM”) to primary care. Key competitors include Cigna (CI), Elevance (ELV), CVS (CVS), Molina (MOH), Humana (HUM) and Centene (CNC), referred to as “peers”.

The author declares an interesting position, and the number of his followers is 256 and it grows, but not that weighty compared to other authors.
White Star Research has 14 analytic reviews published.
The contributor of experts community since 2023

The Share Price of UnitedHealth Group, Inc. (UNH) for now

What analysts predict: $599.98
52-week high/low: $554.7 / $440.66

50/200 Day Moving Average: $523.9 / $507.78

The average stock price over the previous 50/200 days. For UnitedHealth stocks, the 50-day moving average is the resistance level for now. For UNH stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for UNH stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.